Viking Therapeutics soars 22% on trial progress



Viking Therapeutics surged over 22% on Thursday after the biotech company announced its weight loss injection, VK2735, will advance to a late-stage trial ahead of schedule.The development brings the S…
About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento